| Literature DB >> 30190975 |
Nathalie Ganne-Carrié1,2,3,1,2,3, Jean-Charles Nault1,2,3,1,2,3, Marianne Ziol2,3,4,5,2,3,4,5, Gisèle N'Kontchou1,1, Pierre Nahon1,2,3,1,2,3, Véronique Grando1,1, Valérie Bourcier1,1, Sandrine Barge1,2,1,2, Michel Beaugrand1,2,1,2, Jean-Claude Trinchet1,2,3,4,1,2,3,4, Olivier Seror2,3,6,2,3,6.
Abstract
Within 5 years after percutaneous ablation of hepatocellular carcinoma, roughly 70% of patients experience tumor recurrence. Relapses beyond curative options affected patients' survival. Ablation shares with resection common predictive factors of recurrence as size of the tumor, multinodularity and presence of vascular invasion. High serum α-fetoprotein level and markers of severity of underlying liver disease have also been found to be associated with recurrence and even survival. However, predictive values for recurrence of technical factors, histopathological and molecular tumors' features have been rarely studied. Few comparative studies have shown that ablation techniques impact recurrence rates. Moreover, although ablation does not allow analysis of the whole tumor, some reports suggest that biopsies allow histopathological and even molecular testing of the risk of recurrence.Entities:
Keywords: cirrhosis; hepatocellular carcinoma; percutaneous ablation; radiofrequency ablation; recurrence
Year: 2014 PMID： 30190975 PMCID： PMC6095149 DOI： 10.2217/hep.14.22
Source DB: PubMed Journal: Hepat Oncol ISSN： 2045-0923